Ozanimod (Zeposia) became the third oral S1P modulator approved by the FDA for the treatment of multiple sclerosis,
Rahman Gul, PharmD Candidate
Advertisement
Articles by Rahman Gul, PharmD Candidate
Advertisement
Latest Updated Articles
Ozanimod: Treatment for Relapsing Forms of Multiple SclerosisPublished: August 12th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Integrating Combination Therapies for Type 2 Diabetes and CKD
2
Building a Unified Approach to Cardio Kidney Metabolic Health
3
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
4
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
5
